BCM
IONS icon

BlueCrest Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

BlueCrest Capital Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-52,100
Closed -$3.22M – 684
2014
Q4 		$3.22M Buy
+52,100
New +$2.57M 0.1% 194

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BlueCrest Capital Management's IONS Position: Q4 2025 in Review

BlueCrest Capital Management sold out of Ionis Pharmaceuticals (IONS) in Q4 2025, closing a stake of 23,370 shares — an estimated $1.53M sold.

BlueCrest Capital Management first reported a position in IONS in Q4 2014 and held it in 13 quarters. The position peaked at $2.84M in Q1 2019. 491 funds tracked by Wall St. Rank hold IONS as of Q4 2025.

  • BlueCrest Capital Management reported no remaining Ionis Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • BlueCrest Capital Management sold 23,370 Ionis Pharmaceuticals shares in Q4 2025, an estimated $1.53M.
  • BlueCrest Capital Management first reported a position in Ionis Pharmaceuticals in Q4 2014 and held it in 13 quarters.
  • BlueCrest Capital Management's Ionis Pharmaceuticals position peaked at $2.84M in Q1 2019.
  • 491 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2025.

Based on BlueCrest Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.